Popular Articles
Burdock Root

Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (Mesalamine) Delayed-Release Tablets For Moderately Active Ulcerative Colitis
Procter & Gamble Pharmaceuticals (P&GP) announced the availability of Asacol HD (mesalamine) delayed-release tablets, which are indicated for the treatment of moderately active ulcerative colitis (UC), a form of inflammatory bowel disease. UC involves inflammation of the lining of the colon and rectum and is typically characterized by flares followed by periods of remission. Moderately active UC is characterized by tougher symptoms than mildly active UC. Asacol HD is proven to help treat these tougher flares of moderately active UC. Asacol HD was approved by the U.S. Food and Drug Administration (FDA) based on evaluations from the ASCEND studies [Assessing the Safety and Clinical Efficacy of a New Dose of 5-ASA (4.8 g/day 800 mg tablet)].
generic viagra online
Cambridge Consultants Advises Cambridge University's Tech Transfer Arm On IP Strategy
A multidisciplinary team of technology strategists and scientists from Cambridge Consultants has provided advice to Cambridge Enterprise Ltd., regarding potential applications for microdroplet technology in a high-growth sector of the drug discovery market, currently valued at US$140m.
News of the day
Providence Tarzana Surgeon First In U.S. To Use New State-of-the-Art Imaging Tool
Providence Tarzana Medical Center on Friday became the first. hospital in the nation to use the latest generation in imaging - the Ziehm Vision RFD - in this case to aid a surgeon in opening the clogged carotid artery of a patient who had suffered a small stroke.
Public Health

On The Horizon: Effective Over-The-Counter Prostate Cancer Test Kit

An over-the-counter prostate cancer test kit could be coming to a pharmacy near you, thanks to the collaborative work of a University of Central Florida chemist and M.D. Anderson Cancer Center Orlando researchers. UCF"s Qun "Treen" Huo and M.D. Anderson-Orlando"s Dr. Cheryl Baker and Jimmie Colon teamed up about 18 months ago with a very ambitious plan. Huo wanted to develop an effective, inexpensive test to screen for prostate cancer that would be easy enough to use at home or a local pharmacy. "Now cancer tests are so inconvenient and expensive, and a lot of people don"t have insurance, so they are not likely to test if they have no symptoms," Huo said. "Cancer is really scary because there aren"t a lot of symptoms in the early stages. So I said, "Why not create a test that is easy and inexpensive? Then more people can test and catch cancer early so it can be treated early."" Prostate cancer affects one of every six men and is the second-most common cancer among men in the United States, according to the American Cancer Society. It is estimated that more than 2 million American men are currently living with prostate cancer and that one new case occurs every 2.7 minutes. More than 27,000 men die from the disease each year, according to the American Cancer Society. Huo and her team at the UCF lab developed the new technique involving gold nanoparticles, which she first mixes in a solution. The nanoparticles are engineered to attach themselves to cancer-producing proteins related to the type of cancer she is targeting. When she places a drop of blood in the solution, the gold nanoparticles seek out the protein. If the protein is present, the gold nanoparticles cluster around it. Using a dynamic light-scattering instrument, she looks for the clusters. If there are no clusters, there is no cancer-causing protein. During a test, if cancer-producing proteins are detected at a significant level, the consumer would be directed to see a doctor. "Think of it like a pregnancy test," Huo said. "It"s the same principle. Women use it to find out if they are pregnant, but once they see the results at home, they go to the doctor to be sure." The cancer-related protein marker that the gold nanoparticles seek out in Huo"s research is the same one screened for by the FDA-approved Prostate-Specific Antigen (PSA) test. The PSA has a good track record as a protein marker for detecting prostate cancer and has been used by physicians for years. Huo said her new technique is much more sensitive and accurate than the PSA and all current techniques used in diagnostic labs. "What"s different is the technology," Huo said. "It"s very simple. The dynamic light-scattering technique is highly sensitive and can pick up even the smallest trace amount of protein markers." That"s why the technique also can help doctors track any resurgence of cancer once a surgery is performed to remove it. Dr. Baker, director of M.D. Anderson-Orlando"s Cancer Research Institute, collaborates with Huo by offering her expertise in cancer research and by providing human blood and serum samples to test Huo"s technique. "The excitement for us here at M. D. Anderson-Orlando is that we can easily test the validity of the technique in our cancer research program and then on our own patients in a clinical trial," Baker said. "We are optimistic that we can begin clinical trials with this test within the next two years." Huo said that the technique is still years from commercialization, but that in three to five years an over-the-counter test kit for prostate cancer is likely. The technique also can be easily adapted to test for many different types of cancer - Huo plans to focus first on ovarian and breast cancer. Zenaida Gonzalez Kotala University of Central Florida


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):